

Challenges and disincentives for sharing and using data: A researcher perspective

Professor Matthew Sydes

MRC CTU at UCL Institute of Clinical Trials and Methodology London, UK

Sharing Clinical Trial Data: Challenges and a Way Forward: A Workshop 17-Nov-2019

Data sharing at ICTMC 2019

- ICTMC 2019 = conference on clinical trials methodology
 - 730 registered
 - 500 abstracts

- Only 4 (<1%) related to clinical trials data sharing
 - Applicant experiences of CSDR
 - Systematic review of "anonymisation methods"
 - Do data silos jeopardise IPD meta-analyses
 - CTU changing approach





Using data in a valid way and usefulness of new knowledge generated from data sharing

Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data

Using data in a valid way and usefulness of new knowledge generated from data sharing

Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data

Using data in valid way & utility of new knowledge

- Need: maximize highest quality science to have greatest societal benefit
 - Much from clinical trials
 - Much from associated research
- Conscious of opportunity costs
- Effort to prepare datasets
 - Development of trial with view to sharing
 - Preparation and documentation of datasets at "end"
- Effort to support released datasets
 - None if not requested
 - Much if many secondary requests that provoke engagement

Costable

Uncostable

MRC CTU at UCL

Using data in valid way & utility of new knowledge

- Trials analyzed by highly qualified teams with
 - Clear stats planning in design
 - Statistical analysis plans detailing analyses
 - Primary, secondary and exploratory, & accounting for multiple testing
- Trials teams routinely criticized if (perceived to be) doing lots of testing and subgroup analyses
 - Some ICMJE journals will not put subgroups analyses into abstracts
 - Reproducibility crisis in psychological literature
- How to protect trial integrity and integrity of secondary analysis?

Using data in valid way & utility of new knowledge

- Applicants set out analyses in advance
 - Needs to know whether data would be available?
- Applicant qualifications logged?
- "Approved researcher" status register with relevant professional body
- Agree to repeat analyses and do, and work together if differences
- Specific training courses for new researchers seeking data for secondary use?



Using data in a valid way and usefulness of new knowledge generated from data sharing

Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data


2. Which data source and why


- Many applications require trial data
 - e.g. IPD meta-analysis, linkage to samples
- Anticipate proportion of applications do not need individual trials, just good, prospectively collected data
 - e.g. estimating events rates in some subset of patients
 - Trial = convenience sample set for researchers who can't access prospective data when needed
- What if better access to routinely-collected health data (RCHD)*?
 - Good EHR → few applications for trial data?
- Solve issues for access to RCHD at same time or separately to trials?


Using data in a valid way and usefulness of new knowledge generated from data sharing


Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data









TSC = Trial Steering Committee

MRC CTU at UCL

Using data in a valid way and usefulness of new knowledge generated from data sharing

Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data











imdb.com/name/nm0429069

Rashida Jones



Toby Jones imdb.com/name/nm0429363



Chawana Jones

imdb.com/name/nm6398989/

MRC CTU at UCL





Rashida Jones

imdb.com/name/nm0429069









Toby Jones

imdb.com/name/nm0429363



Chawana Jones



Authorship alone does not recognise input



Columns = 10+ editorials and 30+ papers for one clinical trial protocol

Rows = authors (names removed)

Cells = green if named author, red if not

Proposal for recognition



- Would "film credits" for trials improve recognition of effort?
- Would "IMDb for trial engagement" allow recognition and ameliorate some anxieties about data sharing?
 - How might this differ between commercial and non-commercial settings?
- Recognition of researchers involved in creating data
 - Differences between academia and industry?
- DOI for shared datasets.
 - Each version uploaded or one per trial?

New models need buy in from:

- -Journals
- Promotion committees

doi: 10.1056/NEJMc1707245

The NEW ENGLAND JOURNAL of MEDICINE

Data Authorship as an Incentive to Data Sharing

TO THE EDITOR: Eierer et al. (April 27 issue)1 con- THE AUTHORS REPLY: We had hoped to stimulate ceptualize "data authorship" as an incentive for public discussion about how best to align the varydata sharing by clinical trialists. We support sec-ing extant systems to result in one normative sysondary use to advance scientific aims, and the tem to credit persons who contribute and share authors' proposal may start to ameliorate one com-scientific data for secondary use. The proposal monly expressed concern: how the effort of the from Sydes and Ashby to establish an IMDb-like

Two other challenges to mention quickly...

- How / when to properly anonymise / pseudonymise / de-link datasets
 - Dedicated training courses for statisticians and data scientists
 - Could be a specialist (and credited!) role at (larger?) organisations?
- Feedback of results to participants?
 - Getting better at this for main trial results
 - Whose responsibility after data sharing?





Chartuamia



http://www.stampedetrial.org/media-section/news/news-stories/2019/june-2019/m1rt-results-videos/

Summary

Number of challenges

 Addressing them requires buy in secondary data users as well as primary trial researchers and broader trial community

Some Challenges

Using data in a valid way and usefulness of new knowledge generated from data sharing

Rationale for linking to trial data and linkage to routine data for sharing

Oversight processes necessary for access to shared data

Recognition of researchers involved in creating data

MRC CTU at UCL

 Society needs us to find ways to ensure answering the questions that matter in the best way



Challenges and disincentives for sharing and using data: A researcher perspective

Professor Matthew Sydes

MRC CTU at UCL Institute of Clinical Trials and Methodology London, UK

Sharing Clinical Trial Data: Challenges and a Way Forward: A Workshop 17-Nov-2019